Organization and Significant Accounting Policies - Summary of Concentration Risk (Details) - Customer Concentration Risk	6 Months Ended	12 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Revenue \| Pfizer, Inc.
Product Information [Line Items]
Concentration risk	12.20%
Accounts Receivable, net \| Nacalai USA, Inc.
Product Information [Line Items]
Concentration risk		12.00%
Accounts Receivable, net \| Seqirus Inc.
Product Information [Line Items]
Concentration risk	18.30%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.